Entry0.7173→Now0.7287
Undervalued on unpriced Simcere China milestones Open original source
CNTB Connect Biopharma Holdings Limited Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
18:26
Nov 06
Nov 06
r/biotech_stocks
Undervalued on unpriced Simcere China milestones
The author holds CNTB shares and argues the market is ignoring the undisclosed Simcere China licensing milestones for Rademikibart, one of which is likely the China approval milestone and probably the largest portion of the $99M of potential remaining milestone payments. Approval would also allow the drug to be marketed commercially in China, easing the financial worries weighing on the stock. The author expects a recovery past $3 within six months and a potential $1B market cap in 2-5 years, with the main stated risk being the mixed recent study results and the market's negative reaction.
CNTB
Connect Biopharma Holdings Limited
Long
1ST
Position: Holding
—
About CNTB Investor Commentary
Across the available history and selected sources, Buzzberg tracks CNTB (Connect Biopharma Holdings Limited) across 4 sources: 1 bullish vs 0 bearish calls from 5 authors. Historical directional balance: 17% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 6 total trade ideas tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: u/Own-Airline7663.